BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

Phase 1

Terminated

Conditions: Hodgkin Disease
Non-Hodgkins Lymphoma

Interventions: Drug: Infusion of EBV Specific Cytotoxic T-Lymphocytes

First Posted Date: 2003-04-15

Last Posted Date: 2012-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 5

Registration Number: NCT00058773

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts

Phase 1

Completed

Conditions: Epstein-Barr Virus Infections

Interventions: Biological: EBV specific T cells

First Posted Date: 2003-04-15

Last Posted Date: 2015-01-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 69

Registration Number: NCT00058812

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Stem Cell Transplant for Hematologic Diseases

Phase 1

Terminated

Conditions: Hematologic Malignancies

Interventions: Biological: Campath 1H
Drug: Fludarabine
Procedure: Stem Cell Transplant
Radiation: Total Body Irradiation (TBI)
Drug: FK506 (Tacrolimus) or Cyclosporine

First Posted Date: 2003-04-15

Last Posted Date: 2016-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 27

Registration Number: NCT00058825

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: Dose Level 3
Biological: Dose Level 1
Biological: Dose Level 2

First Posted Date: 2003-04-15

Last Posted Date: 2020-01-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 11

Registration Number: NCT00058799

Locations: 🇺🇸
Texas Children's Hospital GCRC, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)

Phase 1

Completed

Conditions: Epstein-Barr Virus Infections

Interventions: Biological: Intravenous injection of EBV specific CTLS

First Posted Date: 2003-04-09

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT00058591

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).

Phase 1

Completed

Conditions: Epstein-Barr Virus Infections
Lymphoproliferative Disorders

Interventions: Biological: Intravenous injection of EBV specific CTLs

First Posted Date: 2003-04-09

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 12

Registration Number: NCT00058604

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

Phase 1

Completed

Conditions: Systemic Sclerosis

First Posted Date: 2003-04-09

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT00058578

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Phase 1

Completed

Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma
EBV Positive Plasma Cell Neoplasm
Epstein-Barr Virus-Related Non-Hodgkin Lymphoma

Interventions: Biological: Injection of EBV Specific CTLs

First Posted Date: 2003-04-09

Last Posted Date: 2017-02-15

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT00058617

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Phase 1

Completed

Conditions: LEUKEMIA

Interventions: Drug: CAMPATH-1H
Drug: Anti-CD45
Drug: Ara-C
Drug: Cyclophosphamide
Drug: Mesna
Radiation: Total Body Irradiation

First Posted Date: 2003-03-28

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 6

Registration Number: NCT00057005

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Phase 1

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: ANTI-CD45
Drug: CAMPATH-1H
Drug: FK506
Drug: Fludarabine
Radiation: Total Body Irradiation
Procedure: Stem cell infusion

First Posted Date: 2003-03-27

Last Posted Date: 2012-06-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT00056966

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy